TABLE 1.
Characteristics of 19 Study Participants Who Underwent NAC for Breast Cancer
| Characteristics | Characteristic Subtype | Value |
|---|---|---|
| Age | Median (Range) 48 | (36–73) |
| Mean (SD) | 49.7 (9.9) | |
| Race or ethnicity | White | 18 (95%) |
| Black or African American | 1 (5%) | |
| Hispanic or Latina | 0 | |
| Asian | 0 | |
| Other | 0 | |
| Unknown | 0 | |
| Menopausal status | Premenopausal | 8 (42%) |
| Perimenopausal | 4 (21%) | |
| Postmenopausal | 7 (37%) | |
| BI-RADS breast density category |
Entirely fat | 0 |
| Scattered fibroglandular densities |
11 (58%) | |
| Heterogeneously dense | 7 (37%) | |
| Extremely dense | 1 (5%) | |
| Receptor status | Hormone receptor positive/ HER-2 negative |
9 (47%) |
| HER-2 positive | 4 (21%) | |
| Triple negative (ER/PR/HER-2 negative) |
6 (32%) | |
| Tumor histology | Invasive ductal carcinoma | 17 (89%) |
| Invasive lobular carcinoma | 0 | |
| Mixed invasive ductal/lobular carcinoma |
2 (11%) | |
| Inflammatory breast cancer |
2 (11%) | |
| Multifocal/multicentric disease |
4 (21%) | |
| Contralateral/bilateral breast cancer |
0 | |
| Tumor size, pretreatment (clinical), mm |
Median (Range) | 40 (0–80) |
| Mean (SD) | 39.2 (21.3) | |
| Tumor size, pretreatment (MRI) |
Median (Range) | 37 (22–98) |
| Mean (SD) | 42.5 (19.3) | |
| Lymph node status at diagnosis |
Positive | 10 (53%) |
| Negative | 9 (47%) | |
| Metastatic status at diagnosis |
Distant metastasis | 0 |
| Neoadjuvant therapy | Doxorubicin/cyclophosphamide/ Paclitaxel |
7 (37%) |
| Carboplatin/paclitaxel | 7 (37%) | |
| Doxorubicin/cyclophosphamide | 2 (11%) | |
| Paclitaxel alone | 2 (11%) | |
| 5-Fluorouracil/epirubicin/ cyclophosphamide |
1 (5%) | |
| Hormonal/biotherapy | Trastuzumab | 4 (21%) |
| Hormonal therapy | 0 | |
| Surgical treatment | Lumpectomy | 5 (26%) |
| Unilateral mastectomy | 2 (11%) | |
| Bilateral mastectomy | 12 (63%) | |
| Clinical response | Clinical complete response | 11 (58%) |
| Partial response | 3 (16%) | |
| Stable disease | 3 (16%) | |
| Progressive disease | 1 (5%) | |
| Missing data | 1 (5%) | |
| Pathological response in the breast |
Complete response | 8 (42%) |
| Residual invasive disease | 11 (58%) | |
| RCB class | RCB-0 | 6 (32%) |
| RCB-1 | 3 (16%) | |
| RCB-2 | 5 (26%) | |
| RCB-3 | 5 (26%) |
BI-RADS indicates Breast Imaging-Reporting and Data System; HER-2, Human Epidermal Growth Factor Receptor 2; ER/PR, estrogen receptor/progesterone receptor.